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As antigenic peptides in the context of human leukocyte antigen (HLA) class I molecules are recognised by cytotoxic T lymphocytes
(CTL), the downregulation of HLA class I molecules is one of the reasons why tumour cells can evade CTL-mediated anti-tumour
immunity. In this study, we investigated HLA class I expression in oesophageal squamous cell carcinoma (ESCC) (n¼70) and in their
metastatic lesions (lymph nodes (n¼40) and liver (n¼3)), by immunohistochemistry with anti-HLA class I monoclonal antibody
(EMR8-5). As a result, the downregulation of HLA class I expression in primary lesions of ESCC was observed in 43%, and that in
metastatic lymph nodes was noted in 90%. Furthermore, patients with preserved HLA class I expression in primary tumours showed
a better survival in comparison to those with downregulated HLA class I molecules (Po0.01). Furthermore, multivariate analysis using
Cox’s proportional hazards model revealed that the downregulated expression of HLA class I in primary lesions was an independent,
unfavourable prognostic factor (Po0.01). In conclusion, the downregulation of HLA class I expression frequently occurred in primary
tumour and, to a greater extent, in metastatic lesions of patients with ESCC and was associated with patient survival.
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Oesophageal squamous cell carcinoma (ESCC) is one of the most
lethal malignancies (Shimada et al, 2003). Despite aggressive
treatment modalities such as surgical tumour resection with
extensive lymphadenectomy and chemo-radiation therapy, the
long-term disease control of advanced-stage ESCC remains
difficult (Akiyama et al, 1994; Ando et al, 2003; Kleinberg and
Forastiere, 2007). Therefore, immunotherapy such as the utilisa-
tion of anti-tumour T cells or antibodies induced by cancer
vaccination is extremely appealing. As the anti-tumour cytotoxic T
lymphocyte (CTL) response is induced by the recognition of
immunogenic epitopes that are presented on various types of HLA
class I molecules on the tumour (Marincola et al, 2000; Tangri
et al, 2001; Cabrera et al, 2007; Nagorsen and Thiel, 2008), it is
important to evaluate the status of HLA class I molecules on
tumour cells. It has been reported that the downregulation of HLA
class I molecules in the tumour commonly occurred, and the defect
of HLA class I molecules is significantly related to patient survival
in several malignancies including ESCC (Hosch et al, 1997a;
Kageshita et al, 1999; Ryschich et al, 2005; Vitale et al, 2005; Ogino
et al, 2006; Ramnath et al, 2006; Speetjens et al, 2008; Ueda et al,
2008). Moreover, it is well known that the downregulation of HLA
class I on the tumour allows it to evade CTL-mediated anti-tumour
immunity, leading to variant cancer cells that arise from the parent
tumour during tumour progression at both primary and metastatic
sites.
Although immunohistochemical analyses of HLA class I expres-
sion in several malignancies have previously been performed, there
was a discrepancy in the frequencies of downregulated HLA class I
molecules (Mattijssen et al, 1991; Mo ¨ller et al, 1991; Passlick et al,
1996; Vora et al, 1997; Ramnath et al, 2006; Kikuchi et al,2 0 0 7 ;
Mehta et al, 2008; Speetjens et al, 2008). This discrepancy might be
due to a difficulty in evaluating immunostaining by anti-MHC class I
monoclonal antibodies (mAbs), such as W6/32, HC-10, or HC-A2, as
these anti-MHC class I mAbs were not appropriate for the
immunostaining of formalin-fixed, paraffin-embedded tissue. Re-
cently, EMR8-5, which is an mAb against HLA class I heavy chains
(HLA-A,B,C), has been confirmed to be valid in HLA class I
immunohistochemistry (Tsukahara et al, 2006; Kikuchi et al,2 0 0 7 ;
Kitamura et al, 2007).
To our knowledge, there have been few reports describing HLA
class I expression in ESCC analysed by previously available mAbs
(Hosch et al, 1997a; Nie et al, 2001). Thus, in this study, we
investigated HLA class I expression in primary and metastatic
lesions (lymph node and liver) in ESCC patients by immunohisto-
chemistry using EMR8-5 mAbs. Furthermore, we evaluated the
correlation between HLA class I expression and the clinicopatho-
logical status or clinical outcome in patients with ESCC.
MATERIALS AND METHODS
Patients and samples
Seventy patients with oesophageal squamous cell carcinoma, who
were operated on in the University of Yamanashi Hospital between
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sApril 5, 1994, and July 27, 2004, were enrolled in this study. Follow-
up duration of the patients was from 49 to 168 months. The
characteristics of the study subjects are summarised in Table 1.
None of the patients received radiotherapy, chemotherapy, or
other medical interventions before the study. This study was
approved by the Ethical Committee of the University of
Yamanashi, and written informed consent was obtained from all
individuals.
Immunohistochemical analysis
Four-micrometre-thick sections of archival, formalin-fixed,
paraffin-embedded tissue blocks (ESCC and adjacent normal
oesophagus) were used for immunohistochemical analysis. For
HLA class I staining, the sections were deparaffinized, followed by
antigen retrieval with epitope retrieval solution (10mmol citrate
buffer (pH 6.0), Dakocytomation) in an autoclave (1211C, 20min).
Endogenous peroxidase was blocked by chemmate peroxidase
blocking solution (Dakocytomation). The primary antibody
EMR8-5 (anti-HLA class I heavy chain, diluted by PBS, 1:100,
Cosmo Bio Co., Tokyo, Japan) was applied to the sections at 41C
overnight. Thereafter, the sections were incubated with the
streptavidin–biotin complex (Simple Stain MAX-PO kit, Nichirei,
Tokyo, Japan) for 30min. The sections were then treated with 3,
30-diaminobenzidine (Dakocytomation) for 5min, and counter-
stained with haematoxylin. Normal epithelium, stromal cells, or
lymphocytes served as a positive control. Negative control staining
was performed with isotype control mAbs (Dakocytomation).
For the evaluation of HLA class I expression, two independent
observers (YM and KK) assessed HLA class I positivity semi-
quantitatively, without previous knowledge of clinicopathological
data. The intensity of HLA class I staining was evaluated using the
following criteria: strong positive (strong), dark brown staining in
more than 50% of tumour cells completely obscuring cytoplasm;
weak positive (weak), any lesser degree of brown staining
appreciable in tumour cells; absent, no appreciable staining in
tumour cells.
Statistical analysis
Actuarial overall survival rates were analysed by the Kaplan–Meier
method, and survival was measured in days from the operation to
death or the last review. Differences between survival curves were
analysed by the log-rank test. Deviation between the population
classified by the intensity of HLA class I expression and
clinicopathological factors was evaluated by the w
2 test.
To assess the correlation between survival time and multiple
clinicopathological variables, univariate and multivariate analyses
were conducted using Cox’s proportional hazards model. Differ-
ences were considered significant at Po0.05. All statistical
analyses were performed with StatView-J 5.0 software (Abacus
Concepts, Berkeley, CA, USA).
RESULTS
Immunohistochemical analysis of HLA class I expression
in ESCC
The intensity of HLA class I staining was semi-quantified by
immunohistochemical staining into strong, weak, and absent
expressions, evaluated by the criteria described in Materials and
Methods, and representative immunostainings are shown in
Figure 1. Summarised data from ESCC (n¼70) indicated that
preserved HLA class I expression (strong) in the primary tumour
was seen in 40 out of 70 patients, weak expression in 24 out of 70
patients, and absent expression in 6 out of 70 patients (Table 2).
The frequencies of the downregulation of HLA class I expression
in the primary tumour were not distributed equally in relation to
the disease progression, such as stage and tumour factors (Table 2).
HLA class I expression between primary tumour and
metastatic site
Out of the total 70 patients, there were 40 with lymph node
metastasis and 3 with hepatic metastasis (1 synchronous and 2
metachronous metastases). Representative immunostainings for
HLA class I molecules in lymph node and hepatic metastases are
shown in Figure 2. As presented in Table 3, 36 (90%) out of 40
patients with lymph node metastasis revealed a downregulation of
HLA class I expression. In particular, even if the primary tumour
exhibited strong HLA class I expression (n¼21), most of the
lymph node metastases (n¼17, 81%) showed the downregulation
of HLA class I expression, indicating that the downregulation of
HLA class I expression frequently occurred according to lymph
node metastasis.
Similarly, all hepatic metastases showed the downregulation of
HLA class I expression, although the number of cases was limited
(n¼3).
Of note, a total loss (absent) of HLA class I expression was noted
in 28% of lymph node and 67% of hepatic metastases.
HLA class I expression relating to survival in ESCC
patients
To investigate the relationship between HLA class I expression and
the clinical outcome, we analysed patient survival relating to HLA
class I expression in the primary tumour. As shown in Figure 3D,
the patients showing the downregulation of HLA class I (weak or
absent) in the primary tumour showed a significantly poorer
prognosis than patients with preserved HLA class I expression
(strong), as well as several other factors, such as T factor
Table 1 Patient and tumour characteristics (n¼70)
Age (years, mean±s.d.) 64.9±8.9
Gender
Male:female 66:4
Tumour size (mm)
Mean (±s.d.) 48.2±21.6
Tumour
a
T1 28
T2 5
T3 34
T4 3
Lymph node metastasis
a
N0 30
N1 40
Histological classification
Well 15
Moderately 38
Poorly 17
Stage
a
I1 4
IIA 16
IIB 16
III 24
IV 0
Abbreviations: Moderately¼moderately differentiated squamous cell carcinoma;
poorly¼poorly differentiated squamous cell carcinoma; well¼well-differentiated
squamous cell carcinoma.
aTumour, lymph node metastasis, and stage according to
the TNM classification for oesophageal cancer (UICC).
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s(Figure 3A), N factor (Figure 3B), and stage classification
(Figure 3C). Moreover, among the metastatic lymph node cases
(n¼40), there was not significant difference in the overall survival
between the cases with further downregulation of HLA class I
status in lymph node metastasis (n¼22) and the remaining 18
cases with consistent class I status between primary and metastatic
lesions (data not shown).
To further assess whether HLA class I expression in the primary
tumour represented a prognostic parameter in patients with ESCC,
we used Cox’s proportional hazards model. The covariate
parameters included several clinicopathological factors in addition
to HLA class I, as shown in Table 4. On univariate analysis, several
factors including HLA class I showed a significantly higher hazard
ratio for a poor prognosis. Moreover, when multivariate analysis
was performed using significant factors in univariate analysis,
multivariate analysis revealed that only HLA class I expression was
an independent prognostic factor (Po0.01, Table 4). These results
clearly indicated that the downregulation of HLA class I expression
in the primary tumour was closely related to a poor prognosis.
DISCUSSION
In this study, the downregulation of HLA class I molecules in the
primary tumour was seen in 43% of ESCC (30 out of 70 cases), and
the frequency of downregulated HLA class I in the metastatic
lymph nodes (90%) was more greatly increased than that in the
primary tumour. In addition, the downregulation of HLA class I
expression in the primary tumours was an independent prognostic
factor showing a higher hazard ratio for a poor prognosis.
Strong expression
Weak expression
Absent expression 
Normal mucosa of oesophagus
HLA class I
Figure 1 Representative immunohistochemical staining of MHC class I molecules in primary lesions of ESCC patients. The intensity of HLA class I staining
was evaluated using the following criteria: strong expression, dark brown staining in more than 50% of tumour cells completely obscuring the cytoplasm (A);
weak expression, any lesser degree of brown staining appreciable in tumour cells (B); absent expression, no appreciable staining in tumour cells (C). Positive
control for HLA class I expression involving normal oesophageal mucosa (D).
Table 2 HLA class I expression of tumours in relation to clinicopatho-
logic status
HLA class I expression in primary lesion
Strong
(n¼40)
Weak
(n¼24)
Absent
(n¼6)
Stage
a
I( n¼14) 12 1 1
IIA (n¼16) 7 8 1 **
IIB (n¼16) 11 2 3
III (n¼24) 10 13 1
Tumour
a
T1 (n¼28) 22 3 3
T2 (n¼5) 1 3 1 **
T3 (n¼34) 15 17 2
T4 (n¼3) 2 1 0
Lymph node metastasis
a
N0 (n¼30) 19 9 2
N1 (n¼40) 21 15 4 NS
Histological classification
Well (n¼15) 7 8 0
Moderately (n¼38) 27 10 1 **
Poorly (n¼17) 6 6 5
Abbreviations: Moderately¼moderately differentiated squamous cell carcinoma; NS¼not
significant; poorly¼poorly differentiated squamous cell carcinoma; Well¼well-
differentiated squamous cell carcinoma. **Po0.05 by the w
2 test.
aTumour, lymph node
metastasis, and stage according to the TNM classification for esophageal cancer (UICC).
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of ESCCs, in line with previous reports (41–45%) involving
analysis using different mAbs for oesophageal cancer (Rockett
et al, 1995; Hosch et al, 1997b). It is most likely that the
downregulation of HLA class I frequently occurred in ESCC, as
the downregulation of HLA class I has been reported at a rate of
10–50% among various types of cancer (Garrido et al, 1997).
This is the first study, to our knowledge, reporting that the
frequency of downregulated HLA class I in the metastatic lymph
nodes was much higher (90% of the case) than that in primary
lesions. Comparative analysis between the primary tumour and
metastasis in the same patient indicated that even if the primary
tumour showed a strong expression of HLA class I molecules,
tumour cells in the lymph node metastasis revealed the
downregulation of HLA class I. Thus, a loss or downregulation
of HLA class I within the primary tumour might be one of the
mechanisms whereby tumour cells spread from primary lesions,
resulting in the establishment of lymph node metastasis.
It has been demonstrated that human tumours with various
histologies have low or downregulated HLA class I molecules due
to the modulation or inhibition of the expression of various HLA
class I antigen-processing machinery (APM) components (Seliger,
2008). Four different phenotypes of altered HLA class I molecules
are known, which are as follows: (i) total HLA loss; (ii) HLA
haplotype loss; (iii) HLA locus loss; and (iv) HLA allelic loss. The
mechanisms involved in the downregulation of HLA class I have
been reported to be genetic mutation or the suppressed trans-
criptional activity of the HLA class I heavy chain or b-2
microglobulin, mutation of the transporter associated with
antigen-processing (TAP) gene, or inhibition of the transport of
HLA class I molecules (Seliger, 2008).
It is well known that abnormality of HLA class I molecules
and APM in tumour cells is one of the major reasons for escape
from CD8(þ) cytotoxic T cells, resulting in disease progression
(Seliger, 2008). However, it has also been shown that tumour cells
without HLA class I molecules appear susceptible to NK cell-
mediated killing due to the involvement of killer-cell inhibitory
receptors on the surface of NK cells, indicating that tumour cells
with a total loss of HLA class I might be killed by NK cell-mediated
immunity (Seliger, 2008). Moreover, tumour cells showing the
downregulation of specific HLA class I alleles could escape from
T-cell-mediated immunity and also avoid NK cell-mediated killing
Lymph node metastasis
HE
HLA class I (absent expression) HLA class I (absent expression)
Liver metastasis
HE
Figure 2 Representative immunohistochemical staining of MHC class I molecules in metastatic lymph nodes (B) and the liver (D) of ESCC patients. Serial
sections for haematoxylin–eosin (HE) staining are shown in (A) and (C).
Table 3 (A) Correlation of HLA class I expression between primary
lesion and lymph node metastasis (n¼40); (B) Correlation of HLA class I
expression between primary lesion and liver metastasis (n¼3)
Lymph node metastasis
Primary lesion
Strong
(n¼4)
Weak
(n¼25)
Absent
(n¼11)
Strong (n¼21) 4 15 2
Weak (n¼15) 0 10 5
Absent (n¼4) 0 0 4
Liver metastasis
Weak
(n¼25)
Absent
(n¼11)
Strong (n¼2) 1 1
Weak (n¼1) 0 1
Absent (n¼0) 0 0
Abbreviations: Absent¼absent expression; strong¼strong expression;
weak¼weak expression.
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These observations suggest that there is a complex association
between the altered HLA class I expression in the tumour and
T-cell or NK cell-mediated immunity. Further detailed studies are
required to evaluate the phenotype of altered HLA class I
molecules in ESCC.
In this study, the downregulation of HLA class I expression
indicated an independent prognostic factor associated with a poor
prognosis in patients with ESCC, in line with a previous report
(Hosch et al, 1997b). Furthermore, we recently reported a
significant correlation between the positivity of peptide-specific
T-cell responses to cancer-testis antigens and preserved HLA class
pT1
pT2
pT3
pT4
S
u
r
v
i
v
a
l
 
r
a
t
e
Postoperative days
Tumour 
pN0
pN1
Lymph node metastasis
Stage I 
Stage II A 
Stage II B 
Stage III 
Stage
n=70
n=70
NS
P < 0.01
0
0.2
0.4
0.6
0.8
1
0 500 1000 1500 2000 2500 3000 3500 4000 4500
0
0.2
0.4
0.6
0.8
1
0 500 1000 1500 2000 2500 3000 3500 4000 4500
0
0.2
0.4
0.6
0.8
1
0 500 1000 1500 2000 2500 3000 3500 4000 4500
n=70
P < 0.01
NS
P < 0.05
S
u
r
v
i
v
a
l
 
r
a
t
e
Postoperative days
S
u
r
v
i
v
a
l
 
r
a
t
e
Postoperative days
HLA class I expression in primary lesion
0
0.2
0.4
0.6
0.8
1
0 500 1000 1500 2000 2500 3000 3500 4000 4500
Strong (n=40)
Weak (n=24)
Absent (n=6)
n=70
P < 0.01
S
u
r
v
i
v
a
l
 
r
a
t
e
Postoperative days
Figure 3 Survival curves in ESCC patients. Kaplan–Meier analyses of the survival of patients with ESCC according to variables are demonstrated as
T factors (A), lymph node metastasis (B), stage (C), and HLA class I expression in primary lesions (D), respectively (n¼70, P-values by the log-rank test).
(D) HLA class I expression in primary lesions was classified into strong (n¼40), weak (n¼24), or absent (n¼6). (A) The median survival time in pT1 was
significantly longer than that in pT3, but there were not significant differences in any other combination. (B) The median survival time in pN0 was significantly
longer than that in pN1. (C) The median survival time in Stage I was significantly longer than that in Stage II B, but there were not significant differences in any
other combination. (D) The median survival time in strong expression was significantly longer than that in weak expression in terms of HLA class I
expression.
Table 4 Univariate and multivariate analyses of patients
Univariate analysis Multivariate analysis
Overall survival Overall survival
Variables Categories HR (95% CI) P-value HR (95% CI) P-value
Age (years) o65 (vs X65) 1.76 (0.85–3.62) 0.13
Gender Male (vs female) 1.80 (0.25–13.21) 0.56
Tumour size (mm) X45 (vs o45) 2.51 (1.20–5.26) 0.014** 1.81 (0.72–4.54) 0.21
Tumour
a T3+T4 (vs T1+T2) 2.73 (1.25–5.95) 0.012** 1.18 (0.44–3.14) 0.74
Lymph node metastasis
a N1 (vs N0) 4.48 (1.91–10.55) o0.01** 2.86 (0.82–10.03) 0.10
Stage
a Stage II+III (vs stage I) 6.55 (1.55–27.73) 0.011** 1.31 (0.22–7.83) 0.77
HLA class I expression Weak+absent (vs strong) 4.03 (1.87–8.70) o0.01** 3.42 (1.40–8.33) o0.01**
Lymphatic invasion Positive (vs negative) 3.18 (1.34–7.52) o0.01** 1.03 (0.32–3.34) 0.96
Vascular invasion Positive (vs negative) 2.74 (1.31–5.75) o0.01** 1.48 (0.58–3.80) 0.42
Histological classification Poorly (vs well+moderately) 1.67 (0.78–3.57) 0.18
Abbreviations: HR¼hazard ratio; 95% CI¼95% confidence interval; moderately¼moderately differentiated squamous cell carcinoma; poorly¼poorly differentiated squamous
cell carcinoma; well¼well-differentiated squamous cell carcinoma. **Po0.05.
aTumour, lymph node metastasis, and stage according to the TNM classification for oesophageal
cancer (UICC).
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These observations suggested that T-cell-mediated immunity
related to HLA class I expression may affect the prognosis of
patients with ESCC. As the downregulation of HLA class I
expression frequently occurred in ESCC, the preservation of HLA
class I expression on tumours might be one of the inclusion
criteria for cancer vaccination therapy for ESCC. Furthermore, the
treatment strategy aiming at restoring HLA class I expression
might be able to improve survival among patients with ESCC or
might lead to successful immunotherapy.
In conclusion, we showed that the downregulation of HLA class
I expression frequently occurred in primary tumours and, to a
greater extent, in metastatic lesions of patients with ESCC and was
associated with patient survival.
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